Valuation: Rigel Pharmaceuticals, Inc.

Market Cap 680M 597M 555M 509M 957M 65.46B 972M 6.59B 2.58B 32.18B 2.55B 2.5B 111B P/E 2026 *
10.5x
P/E 2027 * 10.5x
Enterprise Value 680M 597M 555M 509M 957M 65.46B 972M 6.59B 2.58B 32.18B 2.55B 2.5B 111B EV / Sales 2026 *
2.44x
EV / Sales 2027 * 2x
Free-Float
96.61%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Rigel Pharmaceuticals, Inc.

1 day-0.22%
1 week-9.37%
Current month-6.08%
1 month-0.68%
3 months+21.29%
6 months-0.60%
Current year-14.22%
1 week 35.01
Extreme 35.0057
40.64
1 month 35.01
Extreme 35.0057
43.99
Current year 24.95
Extreme 24.95
49.1
1 year 19.51
Extreme 19.51
52.24
3 years 7.12
Extreme 7.12
52.24
5 years 6.4
Extreme 6.4
52.24
10 years 6.4
Extreme 6.4
55
Manager TitleAgeSince
Chief Executive Officer 65 2014-11-20
Director of Finance/CFO 63 2018-05-28
Compliance Officer 58 2022-11-30
Director TitleAgeSince
Director/Board Member 71 1997-02-28
Director/Board Member 65 2014-11-20
Chairman 67 2022-04-30
Date Insider Type Main position Quantity % Market Cap.
7/8/26 Free

Chief Technology Officer

24,400 0.1319%
6/22/26 Sell

Director

-2,500 0.0135%
6/17/26 Free

Chief Executive Officer

31,700 0.1713%
Change 5-day change 1-year change 3-year change Capi.($)
-0.22%-9.37%+82.15%+192.75% 680M
+0.86%+1.43%+47.17%+161.40% 1,067B
+1.59%+4.09%+56.51%+52.79% 635B
+0.95%+1.91%+36.30%+83.13% 458B
+1.60%+6.25%+37.00%+30.00% 347B
-0.60%+1.52%+36.67%+39.80% 295B
-0.14%+0.60%+17.29%+18.19% 262B
+0.09%-2.82%-29.09%-41.29% 216B
+1.22%+2.66%+22.66%+59.81% 203B
-1.18%-3.70%+11.28%+67.43% 161B
Average +0.42%+0.26%+31.79%+66.40% 364.42B
Weighted average by Cap. +0.76%+1.95%+36.00%+78.17%

Financials

2026 *2027 *
Net sales 279M 245M 228M 209M 393M 26.86B 399M 2.71B 1.06B 13.2B 1.05B 1.02B 45.65B 339M 298M 277M 254M 478M 32.66B 485M 3.29B 1.29B 16.06B 1.27B 1.25B 55.52B
Net income 69.76M 61.27M 56.98M 52.29M 98.25M 6.72B 99.76M 677M 264M 3.3B 262M 256M 11.42B 81M 71.14M 66.16M 60.71M 114M 7.8B 116M 786M 307M 3.84B 304M 298M 13.26B
Net Debt - -
Logo Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing therapies for patients with hematologic disorders and cancer. It focuses on products that address signaling pathways that are critical to disease mechanisms. Its products include TAVALISSE, REZLIDHIA, and GAVRETO. TAVALISSE is an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. REZLIDHIA is used for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. GAVRETO is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions. It is used for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory.
Employees
173
Date Price Change Volume
26-07-24 US$36.74 -0.22% 485,299
26-07-23 US$36.82 -2.59% 383,198
26-07-22 US$37.80 -3.84% 331,743
26-07-21 US$39.31 -0.91% 456,768
26-07-20 US$39.67 -2.15% 363,057
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
36.74USD
Average target price
55.20USD
Spread / Average Target
+50.24%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RIGL Stock